Opening the book…
A medicine moves from discovery through nonclinical and clinical studies, FDA review, and oversight after approval. The evidence at each stage helps teams decide whether to continue, change direction, or stop. An IND supports covered research in people. Marketing applications ask FDA to evaluate the evidence, labeling, and manufacturing controls for a proposed product and use.
Quality assurance supports consistent work through procedures, training, and oversight. Quality control checks materials and products against requirements. After approval, complaint patterns and safety reports can prompt investigations. Traceability helps the team identify affected lots and contact the people who received them. The McNeil case shows why timely investigations, management follow-through, and checks on corrective actions matter.
Key Terms
|
active pharmaceutical ingredient (API) |
drug product |
therapeutic biological product |
|
biopharmaceutical |
quality assurance (QA) |
quality control (QC) |
|
high-throughput screening (HTS) |
ADME |
toxicology |
|
investigational new drug application (IND) |
good clinical practice (GCP) |
institutional review board (IRB) |
|
informed consent |
randomization |
masking |
|
bioresearch monitoring (BIMO) |
new drug application (NDA) |
biologics license application (BLA) |
|
abbreviated new drug application (ANDA) |
bioavailability |
bioequivalence |
|
priority review |
orphan drug designation |
accelerated approval |
|
surrogate endpoint |
fast track |
breakthrough therapy designation |
|
tentative approval |
cross-contamination |
cleaning validation |
|
postmarket surveillance |
traceability |
Form FDA 483 |
|
warning letter |
consent decree |
corrective and preventive actions (CAPA) |
|
continuous improvement |
current good manufacturing practice (cGMP) |
|
Review Questions
1. How do a drug substance and a finished drug product differ?
2. What does ADME stand for, and what does it help researchers understand?
3. What three types of information does an IND provide?
4. What questions do Phases 1, 2, and 3 generally address?
5. How do informed consent and IRB review protect participants?
6. What does FDA evaluate in an NDA or BLA? How does an ANDA use evidence about a reference drug?
7. How do priority review, accelerated approval, and orphan designation differ?
8. How do supplier controls and cleaning validation help prevent contamination?
9. How can traceability help a manufacturer define the scope of a recall?
10. How do Class I, II, and III recalls differ?
11. What are the purposes of Form FDA 483, a warning letter, and a consent decree?
Apply Your Understanding
1. A candidate enzyme shows promising activity in cultured cells. A manager wants to begin giving it to volunteers immediately. Identify the additional evidence, manufacturing information, and participant protections that should be addressed before a covered clinical investigation begins.
2. A team plans to transfer production of a clinical study material to a larger vessel. Explain why scale-up is more than a change in volume. What information could help determine whether material made at the new scale remains suitable for the study?
3. A hypothetical candidate improves a laboratory marker but causes frequent severe side effects. Explain why the marker alone does not settle the benefit-risk question. What additional information would help interpret the findings?
4. A manufacturer detects residue from a previous product after cleaning shared equipment. The next batch passes its final tests. Explain why those tests alone do not settle the concern and identify evidence needed before a disposition decision.
5. An inspection ends with one Form FDA 483 observation about incomplete investigations. Management calls it minor because there is only one observation. Explain why this reasoning is inadequate and propose a response with evidence, actions, responsibilities, and effectiveness checks.
6. Using the documented McNeil case, identify two points where stronger investigation, communication, or management oversight could have improved the response. Propose two measures that would help evaluate whether complaint handling is improving.
This page titled 12.9: Chapter Summary was last modified on Thu, 05 Nov 2026 12:43:41 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.